BMS is showcasing Cobenfy at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Cobenfy IS the story at APA 2026. First new mechanism of action for schizophrenia in over 30 years — every psychiatrist in the room knows about it. BMS will be promoting year-1 real-world experience, differentiation from D2 antagonists (no metabolic syndrome, no tardive dyskinesia, no prolactin elevation), and teasing the expansion indications. Their sole registered attendee is a Senior Director of US Medical Affairs — this is a high-value, evidence-focused conversation.
Ask about: Year-1 prescribing data and real-world experience; metabolic advantage evidence in practice; ARISE adjunctive trial follow-up (missed primary endpoint — what's next?); ADEPT-2 enrollment in Alzheimer's psychosis; bipolar I and ASD irritability trial design/timelines; formulary access and payer reception; how psychiatrists are using Cobenfy in treatment algorithms (first-line vs. switch). Their attendee James Appio (Sr. Director US Med Affairs) will want a scientifically rigorous conversation.
Cobenfy's first-in-class MOA needs robust RWE to prove real-world differentiation — this is year 1, the most critical evidence window. VoiceVitals captures continuous schizophrenia symptom data (speech poverty, disorganization, affective flattening) between visits. ePRO+ supports real-world outcomes measurement that goes beyond PANSS. For ADEPT-2 (AD psychosis), VoiceVitals' agitation/psychosis detection in cognitively impaired patients is directly relevant.
Position as the RWE infrastructure partner during the critical launch window. ARISE trial missed — Videra's enriched data could help identify responder subpopulations for redesigned trials.
Set up a follow-up with BMS's team and Videra Health.
Email Ryan Roberts →